查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1944397

全球類肉瘤病藥物市場：按作用機制、給藥途徑、藥物類型、最終用途、年齡層、適應症、國家和地區分類－產業分析、市場規模、佔有率和預測（2025-2032）

Sarcoidosis Drug Market, By Mechanism of Action, By Route of Administration, By Drug, By Type, By End-Use, By Age Group, By Indication, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 329 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到 2024 年，類肉瘤病治療市場價值將達到 72.011 億美元，從 2025 年到 2032 年，複合年成長率將達到 6.12%。

類肉瘤病治療市場涵蓋用於治療類肉瘤病的藥物。結節性多發性硬化症是一種發炎性疾病，其特徵是肺部、皮膚和淋巴結等器官中形成肉芽腫。自體免疫疾病和發炎性疾病盛行率的上升、診斷率的提高以及臨床意識的增強是推動市場成長的關鍵因素。為了減輕副作用，市場正逐步從長期使用皮質類固醇轉向免疫抑制劑和生物製藥。然而，核准的疾病特異性藥物寥寥無幾，疾病的異質性仍是一個主要障礙。儘管如此，透過持續的臨床研究、孤兒藥的開發以及生物目標的研發，改善患者的長期預後和提高治療的精準度仍蘊藏著新的機會。

結節性類肉瘤病硬化症藥物的市場動態

更加重視研發

類肉瘤病治療市場正日益受到研發工作的推動，這些研發工作旨在推動新型治療方法的研發並改善病患的治療效果。這種關注正促使標靶治療和個人化醫療方法被廣泛採用，以更好地應對疾病的臨床複雜性。目前，結節性多發性硬化症的治療主要依賴皮質類固醇和免疫抑制劑的仿單標示外用藥，而這些藥物往往有安全隱患且療效不一。因此，開發替代治療方案仍是當務之急。

例如，2025年2月，Roivant Sciences宣布計畫啟動一項針對成人皮膚類肉瘤病病患者的口服雙重TYK2/JAK1抑制劑brepoxitinib的II期臨床試驗。該試驗預計於2026年4月開始，結果預計於2026年下半年公佈。

類肉瘤病治療市場：細分分析

全球類肉瘤病藥物市場按作用機制、給藥途徑、藥物、類型、最終用途、年齡層、適應症和地區進行細分。

肺類肉瘤病以肺部肉芽腫為特徵，是類肉瘤病治療市場中最常見的類型（佔所有類肉瘤病病患者的90%），因此佔了相當大的佔有率。如此高的發生率凸顯了針對肺部表現的標靶治療和研究的必要性。其市場主導地位與高發病率、對創新治療方法的持續探索以及醫護人員和患者日益增強的認知密切相關。肺動脈高壓和永久性肺纖維化等嚴重更凸顯了標靶治療的必要性。 2022年11月，Kinevant Sciences啟動了RESOLVE-Lung試驗，旨在評估靶向GM-CSF的單株抗體namilumab治療肺類肉瘤病的療效。該試驗共有107名受試者，預計2024年底公佈初步結果。

預計到2025年，潑尼松將在藥物治療市場佔據主導地位，成為類肉瘤病治療的主要藥物。這主要歸功於其作為類肉瘤病一線治療藥物的廣泛認可。作為一種皮質類固醇，潑尼松能夠降低免疫反應、發炎反應並緩解症狀，尤其是在呼吸系統方面。臨床指引始終推薦潑尼松作為標準治療方案，凸顯了其作為基礎治療的重要性。潑尼鬆的廣泛接受度、價格適中以及在臨床實踐中的應用，使其成為醫療專業人員常用的長期治療選擇。潑尼鬆在控制發炎方面的有效性及其廣泛的應用，鞏固了其市場主導地位。根據2020年的一項研究，59.3%的類肉瘤病病患者接受了皮質類固醇治療，其中24.7%的患者接受了長期治療。長期使用以及顯著的副作用，凸顯了開發更安全、更有效治療方法的必要性。

類肉瘤病藥物市場－區域分析

北美地區在類肉瘤病治療市場佔據重要佔有率，這主要歸功於該地區結節病病例高發，尤其是累及心臟的病例；此外，該地區擁有完善的醫療基礎設施、活躍的研發項目，以及製藥公司、學術機構、醫學專家和患者權益組織之間的密切合作。北美地區成熟的醫療基礎設施能夠實現類肉瘤病的早期發現和強化治療，為患者提供專業的治療和最新的藥物。隨著領先的製藥公司和研究機構攜手合作，共用知識，加速疾病管理，類肉瘤病的治療也不斷取得進展。

2024 年 4 月，類肉瘤病研究基金會與沃爾格林合作，提高人們對類肉瘤病的認知，並在阿拉巴馬州推廣春季疫苗接種，強調結節病對社區的影響，並鼓勵捐款以支持研究和患者支持舉措。

美國類肉瘤病藥物市場—國家分析

2024年，美國類肉瘤病治療市場在北美佔據了顯著的收入佔有率。這主要歸功於該疾病在非裔美國人中的高發病率（非裔美國人尤其容易發展為重症），以及美國完善的醫療保健系統、廣泛的研發活動和大型製藥公司的強大影響力。美國患者能夠獲得先進的診斷技術和多種治療方法，包括新型生物製藥和孤兒藥。對類肉瘤病研究的大力投入，以及學術機構與產業相關人員之間的戰略合作，正在推動市場成長，並使美國成為類肉瘤病治療藥物研發和推廣領域的領導者。

目錄

第1章類肉瘤病藥物市場概覽

  • 分析範圍
  • 市場估算期

第2章執行摘要

  • 市場區隔
  • 競爭考察

第3章 結節性類肉瘤病藥物的主要市場趨勢

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 未來市場趨勢

第4章類肉瘤病治療市場：產業分析

  • PEST分析
  • 波特五力分析
  • 市場成長展望：概覽
  • 管理體制分析

第5章類肉瘤病藥物市場：地緣政治緊張局勢加劇的影響

  • 新冠疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章 結節性類肉瘤病藥物市場狀況

  • 類肉瘤病治療市佔率分析（2024 年）
  • 主要製造商的細分數據
    • 對現有公司的分析
    • 新興企業分析

第7章 依作用機轉分類的類肉瘤病治療市場

  • 概述
    • 細分市場佔有率分析：依作用機制分類
    • 抗瘧疾藥
    • 免疫抑制劑
    • 腫瘤壞死因子-α (TNF-α) 抑制劑
    • 皮質類固醇

第8章類肉瘤病藥物市場依給藥途徑分類

  • 概述
    • 細分市場佔有率分析：依管理途徑
    • 注射
    • 口服
    • 局部的

第9章類肉瘤病藥物市場（依藥物分類）

  • 概述
    • 細分市場佔有率分析：依藥物分類
    • 羥氯喹
    • Azathioprine
    • 促腎上腺皮質激素
    • 地塞米松
    • 秋水仙鹼
    • Chloroquine
    • 強的松
    • 胺基甲基葉酸
    • 德爾塔區

第10章 按類型分類的類肉瘤病藥物市場

  • 概述
    • 細分市場佔有率分析：按類型
    • 肝類肉瘤病
    • 腎類肉瘤病
    • 脾臟和骨髓類肉瘤病
    • 肺結節類肉瘤病
    • 肌肉骨骼類肉瘤病
    • 皮膚類肉瘤病
    • 眼部類肉瘤病
    • 心臟類肉瘤病
    • 類肉瘤病

第11章 依最終用途分類的類肉瘤病治療市場

  • 概述
    • 細分市場佔有率分析：依最終用途分類
    • 手術中心
    • 醫院和診所
    • 診斷中心
    • 其他

第12章 按年齡層別分類的類肉瘤病藥物市場

  • 概述
    • 細分市場佔有率分析：依年齡層別分類
    • 兒童
    • 成人
    • 老年人

第13章類肉瘤病藥物市場（依適應症分類）

  • 概述
    • 細分市場佔有率分析：依指標
    • 肺外結節類肉瘤病
    • 肺結節類肉瘤病

第14章 各地區類肉瘤病治療市場

  • 介紹
  • 北美洲
    • 概述
    • 北美主要製造商
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲主要製造商
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 其他
  • 亞太地區
    • 概述
    • 亞太地區主要製造商
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 其他
  • 拉丁美洲
    • 概述
    • 拉丁美洲主要製造商
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 其他
  • 中東和非洲
    • 概述
    • 中東和非洲的主要製造商
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • 其他

第15章 主要供應商分析—類肉瘤病治療產業

  • 競爭對手儀錶板
    • 競爭基準
    • 競爭定位
  • 公司簡介
    • Janssen Pharmaceutical Companies of Johnson &Johnson
    • Pfizer Inc
    • Amgen Inc.
    • Bristol Myers Squibb
    • Novartis AG
    • Kinevant Sciences GmbH
    • Molecure SA
    • aTyr Pharma
    • Merck &Co., Inc
    • Xentria
    • United Therapeutics Corporation
    • Relief Therapeutics
    • Mallinckrodt
    • AbbVie Inc.
    • Kyorin Pharmaceutical Co., Ltd.
    • Boehringer Ingelheim International GmbH
    • Sanofi
    • GSK plc.
    • Theravance Biopharma
    • Others

第16章：分析師視角

簡介目錄
Product Code: ANV6020

Sarcoidosis Drug Market size was valued at US$ 7,201.10 Million in 2024, expanding at a CAGR of 6.12% from 2025 to 2032.

The Sarcoidosis Drug Market includes pharmaceutical therapies used to treat sarcoidosis, an inflammatory disease characterized by granuloma formation in organs such as the lungs, skin, and lymph nodes. The rising prevalence of autoimmune and inflammatory disorders, increased diagnosis rates, and improved clinical awareness are the primary drivers of market growth. To reduce side effects, the market is gradually shifting away from long-term corticosteroid use and toward immunosuppressants and biologic therapies. However, there are few disease-specific drugs that have been approved, and disease heterogeneity is still a major barrier. Despite this, opportunities are emerging through ongoing clinical research, orphan drug development, and targeted biologics to improve long-term patient outcomes and treatment precision.

Sarcoidosis Drug Market- Market Dynamics

Increased emphasis on research and development

The sarcoidosis drug market is increasingly shaped by intensive research and development efforts aimed at advancing novel therapies and enhancing patient outcomes. This focus has encouraged the adoption of targeted treatments and personalized medicine approaches to better manage the disease's clinical complexity. At present, treatment largely depends on the off-label use of corticosteroids and immunosuppressants, which are often associated with safety concerns and variable therapeutic effectiveness. Consequently, the development of alternative treatment options remains a critical priority.

For instance, in February 2025, Roivant Sciences announced plans to initiate a Phase II clinical trial of brepocitinib, an oral dual TYK2 and JAK1 inhibitor, for the treatment of adults with cutaneous sarcoidosis. The study is scheduled to commence in April 2026, with results anticipated in the latter half of 2026.

Sarcoidosis Drug Market- Segmentation Analysis:

The Global Sarcoidosis Drug Market is segmented on the basis of Mechanism of Action, Route of Administration, Drug, Type, End-Use, Age Group, Indication, and Region.

The pulmonary sarcoidosis segment accounts for a significant share of the sarcoidosis drug market because it is distinguished by the presence of granulomas in the lungs and is the most common type of sarcoidosis, affecting 90% of people. The high prevalence highlights the need for targeted treatments and investigations into pulmonary symptoms. Market dominance is associated with higher prevalence rates, ongoing research into innovative therapies, and increased awareness among healthcare providers and patients. Serious conditions like pulmonary hypertension and permanent lung fibrosis highlight the need for targeted treatments. In November 2022, Kinevant Sciences initiated the RESOLVE-Lung study to evaluate namilumab, a monoclonal antibody that targets GM-CSF, for the treatment of pulmonary sarcoidosis. The study, which included 107 participants, is expected to produce preliminary findings by the end of 2024.

Based on the Drug: Prednisone dominate the sarcoidosis drug market in 2025 because it is widely recognized as the primary treatment for sarcoidosis. As a corticosteroid, it reduces immune response, inflammation, and symptoms, particularly in respiratory cases. Clinical guidelines consistently recommend prednisone as the standard therapy, emphasizing its importance as a foundational treatment. Its widespread acceptance, affordability, and clinical familiarity make it a popular choice among healthcare professionals for prolonged treatment. Prednisone's effectiveness in inflammation management, combined with its widespread use, contributed to its market prevalence. According to the 2020 study, 59.3% of sarcoidosis patients are treated with corticosteroids, while 24.7% receive long-term treatment. The prolonged use, combined with significant side effects, emphasizes the need for safer and more effective treatment options.

Sarcoidosis Drug Market- Geographical Insights

North America holds significant share in the sarcoidosis drug market due to its high prevalence, especially with cardiac involvement, robust healthcare infrastructure, active research and development programs, and partnerships between pharmaceutical companies, academic entities, healthcare professionals, and patient advocacy organizations. The region's well-established healthcare infrastructure allows early detection and thorough management of sarcoidosis, providing patients with specialized treatment and the latest medicines. Sarcoidosis therapy advances with major pharmaceutical companies and research organizations, which collaborate to share knowledge and accelerate disease management.

In April 2024, the Foundation for Sarcoidosis Research partnered with Walgreens to raise sarcoidosis awareness and promote spring vaccinations in Alabama, emphasizing community impact and encouraging donations to research and patient assistance initiatives.

United States Sarcoidosis Drug Market- Country Insights

The U.S. sarcoidosis drug market accounted for a sizable revenue share in North America in 2024, owing to the disease's high prevalence, particularly among African Americans, who frequently suffer from more severe forms of the disease. This is complemented by a well-developed healthcare system, extensive research and development activities, and a strong presence of major pharmaceutical corporations. Patients in the United States have access to advanced diagnostics and a wide range of therapies, including novel biologics and orphan drugs. Strong funding for sarcoidosis research, as well as strategic collaborations between academic institutions and industry players, are driving market growth and establishing the United States as a leader in sarcoidosis drug development and adoption.

Sarcoidosis Drug Market- Competitive Landscape:

The sarcoidosis drug market is moderately competitive, with established pharmaceutical companies and emerging players offering anti-inflammatory, immunosuppressive, and biologic therapies. Market participants compete primarily based on product efficacy, safety profiles, and expanded indications. Corticosteroids remain the primary first-line treatment, but immunosuppressants and biologics are gaining popularity for chronic and refractory cases. Companies are also investing in clinical trials and pipeline expansion to meet unmet medical needs, particularly for steroid-free treatments. Strategic collaborations, research partnerships, and regulatory approvals all play an important role in maintaining market positions. Key players in the sarcoidosis drug market include Novartis AG, Kinevant Sciences GmbH, Molecure S.A, aTyr Pharma, all of which rely on strong R&D capabilities and global distribution networks to stay competitive.

In November 2024, The Foundation for Sarcoidosis Research awarded Dr. Eliot Peyster and Dr. Ravi Karra USD 100,000 to advance the diagnosis and treatment of cardiac sarcoidosis, with a focus on establishing new diagnostic benchmarks and reusing imaging agents.

Recent Developments:

In April 2024, aTyr Pharma has launched a global Phase III EFZO-FIT(TM) trial to assess efzofitimod, an innovative treatment aimed at neuropilin-2 for pulmonary sarcoidosis that has been granted orphan drug designations in the U.S., EU, and Japan.

In March 2025, Xentria, Inc. reported significant progress in its XTMAB-16 study for pulmonary sarcoidosis, including the successful enrollment of patients in the dose-ranging study. XTMAB-16 is a new anti-TNF-a monoclonal antibody being developed as a potential treatment for pulmonary sarcoidosis. This advancement demonstrates Xentria's commitment to addressing the unmet need for targeted therapies in sarcoidosis, with the next phase of research, which will include additional patient screening, set to begin in Fall 2025.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL SARCOIDOSIS DRUG MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Janssen Pharmaceutical Companies of Johnson & Johnson
  • Pfizer Inc
  • Amgen Inc.
  • Bristol Myers Squibb
  • Novartis AG
  • Kinevant Sciences GmbH
  • Molecure S.A
  • aTyr Pharma
  • Merck & Co., Inc
  • Xentria
  • United Therapeutics Corporation
  • Relief Therapeutics
  • Mallinckrodt
  • AbbVie Inc.
  • Kyorin Pharmaceutical Co., Ltd.
  • Boehringer Ingelheim International GmbH
  • Sanofi
  • GSK plc.
  • Theravance Biopharma
  • Others

GLOBAL SARCOIDOSIS DRUG MARKET, BY MECHANISM OF ACTION- MARKET ANALYSIS, 2019 - 2032

  • Antimalarial
  • Immunosuppressants
  • Tumor Necrosis Factor-alpha (TNF-Alpha) Inhibitors
  • Corticosteroid

GLOBAL SARCOIDOSIS DRUG MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Injectable
  • Oral
  • Topical

GLOBAL SARCOIDOSIS DRUG MARKET, BY DRUG- MARKET ANALYSIS, 2019 - 2032

  • Hydroxychloroquine
  • Azathioprine
  • Corticotropin
  • Dexamethasone
  • Colchicine
  • Chloroquine
  • Prednisone
  • Methotrexate
  • Deltasone

GLOBAL SARCOIDOSIS DRUG MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Hepatic Sarcoidosis
  • Renal Sarcoidosis
  • Sarcoidosis of the Spleen and Bone Marrow
  • Pulmonary Sarcoidosis
  • Musculoskeletal Sarcoidosis
  • Cutaneous Sarcoidosis
  • Ocular Sarcoidosis
  • Cardiac Sarcoidosis
  • Neurosarcoidosis

GLOBAL SARCOIDOSIS DRUG MARKET, BY END-USE- MARKET ANALYSIS, 2019 - 2032

  • Surgical Centers
  • Hospitals & Clinics
  • Diagnostic Centers
  • Others

GLOBAL SARCOIDOSIS DRUG MARKET, BY AGE GROUP- MARKET ANALYSIS, 2019 - 2032

  • Pediatric
  • Adult
  • Geriatric

GLOBAL SARCOIDOSIS DRUG MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032

  • Extrapulmonary Sarcoidosis
  • Pulmonary Sarcoidosis

GLOBAL SARCOIDOSIS DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Sarcoidosis Drug Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Sarcoidosis Drug Market Snippet by Mechanism of Action
    • 2.1.2. Sarcoidosis Drug Market Snippet by Route of Administration
    • 2.1.3. Sarcoidosis Drug Market Snippet by Drug
    • 2.1.4. Sarcoidosis Drug Market Snippet by Type
    • 2.1.5. Sarcoidosis Drug Market Snippet by End-Use
    • 2.1.6. Sarcoidosis Drug Market Snippet by Age Group
    • 2.1.7. Sarcoidosis Drug Market Snippet by Indication
    • 2.1.8. Sarcoidosis Drug Market Snippet by Country
    • 2.1.9. Sarcoidosis Drug Market Snippet by Region
  • 2.2. Competitive Insights

3. Sarcoidosis Drug Key Market Trends

  • 3.1. Sarcoidosis Drug Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Sarcoidosis Drug Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Sarcoidosis Drug Market Opportunities
  • 3.4. Sarcoidosis Drug Market Future Trends

4. Sarcoidosis Drug Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Sarcoidosis Drug Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Sarcoidosis Drug Market Landscape

  • 6.1. Sarcoidosis Drug Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Sarcoidosis Drug Market - By Mechanism of Action

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Mechanism of Action, 2024 & 2032 (%)
    • 7.1.2. Antimalarial
    • 7.1.3. Immunosuppressants
    • 7.1.4. Tumor Necrosis Factor-alpha (TNF-Alpha) Inhibitors
    • 7.1.5. Corticosteroid

8. Sarcoidosis Drug Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 8.1.2. Injectable
    • 8.1.3. Oral
    • 8.1.4. Topical

9. Sarcoidosis Drug Market - By Drug

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Drug, 2024 & 2032 (%)
    • 9.1.2. Hydroxychloroquine
    • 9.1.3. Azathioprine
    • 9.1.4. Corticotropin
    • 9.1.5. Dexamethasone
    • 9.1.6. Colchicine
    • 9.1.7. Chloroquine
    • 9.1.8. Prednisone
    • 9.1.9. Methotrexate
    • 9.1.10. Deltasone

10. Sarcoidosis Drug Market - By Type

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
    • 10.1.2. Hepatic Sarcoidosis
    • 10.1.3. Renal Sarcoidosis
    • 10.1.4. Sarcoidosis of the Spleen and Bone Marrow
    • 10.1.5. Pulmonary Sarcoidosis
    • 10.1.6. Musculoskeletal Sarcoidosis
    • 10.1.7. Cutaneous Sarcoidosis
    • 10.1.8. Ocular Sarcoidosis
    • 10.1.9. Cardiac Sarcoidosis
    • 10.1.10. Neurosarcoidosis

11. Sarcoidosis Drug Market - By End-Use

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By End-Use, 2024 & 2032 (%)
    • 11.1.2. Surgical Centers
    • 11.1.3. Hospitals & Clinics
    • 11.1.4. Diagnostic Centers
    • 11.1.5. Others

12. Sarcoidosis Drug Market - By Age Group

  • 12.1. Overview
    • 12.1.1. Segment Share Analysis, By Age Group, 2024 & 2032 (%)
    • 12.1.2. Pediatric
    • 12.1.3. Adult
    • 12.1.4. Geriatric

13. Sarcoidosis Drug Market - By Indication

  • 13.1. Overview
    • 13.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
    • 13.1.2. Extrapulmonary Sarcoidosis
    • 13.1.3. Pulmonary Sarcoidosis

14. Sarcoidosis Drug Market- By Geography

  • 14.1. Introduction
    • 14.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 14.2. North America
    • 14.2.1. Overview
    • 14.2.2. Sarcoidosis Drug Key Manufacturers in North America
    • 14.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.2.4. North America Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 14.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 14.2.6. North America Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.2.7. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.2.8. North America Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.2.9. North America Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 14.2.10. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.2.11. U.S.
      • 14.2.11.1. Overview
      • 14.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.2.11.3. U.S. Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.2.11.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.2.11.5. U.S. Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.2.11.6. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.2.11.7. U.S. Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.2.11.8. U.S. Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.2.11.9. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.2.12. Canada
      • 14.2.12.1. Overview
      • 14.2.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.2.12.3. Canada Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.2.12.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.2.12.5. Canada Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.2.12.6. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.2.12.7. Canada Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.2.12.8. Canada Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.2.12.9. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 14.3. Europe
    • 14.3.1. Overview
    • 14.3.2. Sarcoidosis Drug Key Manufacturers in Europe
    • 14.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.3.4. Europe Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 14.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 14.3.6. Europe Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.3.7. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.3.8. Europe Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.3.9. Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 14.3.10. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.11. Germany
      • 14.3.11.1. Overview
      • 14.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.11.3. Germany Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.11.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.11.5. Germany Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.11.6. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.11.7. Germany Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.11.8. Germany Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.11.9. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.12. UK
      • 14.3.12.1. Overview
      • 14.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.12.3. UK Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.12.4. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.12.5. UK Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.12.6. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.12.7. UK Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.12.8. UK Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.12.9. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.13. France
      • 14.3.13.1. Overview
      • 14.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.13.3. France Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.13.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.13.5. France Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.13.6. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.13.7. France Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.13.8. France Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.13.9. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.14. Italy
      • 14.3.14.1. Overview
      • 14.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.14.3. Italy Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.14.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.14.5. Italy Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.14.6. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.14.7. Italy Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.14.8. Italy Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.14.9. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.15. Spain
      • 14.3.15.1. Overview
      • 14.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.15.3. Spain Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.15.4. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.15.5. Spain Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.15.6. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.15.7. Spain Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.15.8. Spain Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.15.9. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.16. The Netherlands
      • 14.3.16.1. Overview
      • 14.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.16.3. The Netherlands Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.16.4. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.16.5. The Netherlands Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.16.6. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.16.7. The Netherlands Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.16.8. The Netherlands Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.16.9. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.17. Sweden
      • 14.3.17.1. Overview
      • 14.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.17.3. Sweden Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.17.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.17.5. Sweden Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.17.6. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.17.7. Sweden Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.17.8. Sweden Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.17.9. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.18. Russia
      • 14.3.18.1. Overview
      • 14.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.18.3. Russia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.18.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.18.5. Russia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.18.6. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.18.7. Russia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.18.8. Russia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.18.9. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.19. Poland
      • 14.3.19.1. Overview
      • 14.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.19.3. Poland Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.19.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.19.5. Poland Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.19.6. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.19.7. Poland Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.19.8. Poland Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.19.9. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.3.20. Rest of Europe
      • 14.3.20.1. Overview
      • 14.3.20.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.3.20.3. Rest of the Europe Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.3.20.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.3.20.5. Rest of the Europe Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.3.20.6. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.3.20.7. Rest of the Europe Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.3.20.8. Rest of the Europe Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.3.20.9. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 14.4. Asia Pacific (APAC)
    • 14.4.1. Overview
    • 14.4.2. Sarcoidosis Drug Key Manufacturers in Asia Pacific
    • 14.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.4.4. APAC Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 14.4.5. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 14.4.6. APAC Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.4.7. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.4.8. APAC Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.4.9. APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 14.4.10. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.11. China
      • 14.4.11.1. Overview
      • 14.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.11.3. China Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.11.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.11.5. China Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.11.6. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.11.7. China Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.11.8. China Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.11.9. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.12. India
      • 14.4.12.1. Overview
      • 14.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.12.3. India Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.12.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.12.5. India Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.12.6. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.12.7. India Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.12.8. India Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.12.9. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.13. Japan
      • 14.4.13.1. Overview
      • 14.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.13.3. Japan Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.13.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.13.5. Japan Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.13.6. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.13.7. Japan Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.13.8. Japan Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.13.9. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.14. South Korea
      • 14.4.14.1. Overview
      • 14.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.14.3. South Korea Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.14.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.14.5. South Korea Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.14.6. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.14.7. South Korea Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.14.8. South Korea Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.14.9. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.15. Australia
      • 14.4.15.1. Overview
      • 14.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.15.3. Australia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.15.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.15.5. Australia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.15.6. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.15.7. Australia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.15.8. Australia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.15.9. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.16. Indonesia
      • 14.4.16.1. Overview
      • 14.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.16.3. Indonesia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.16.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.16.5. Indonesia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.16.6. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.16.7. Indonesia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.16.8. Indonesia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.16.9. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.17. Thailand
      • 14.4.17.1. Overview
      • 14.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.17.3. Thailand Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.17.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.17.5. Thailand Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.17.6. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.17.7. Thailand Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.17.8. Thailand Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.17.9. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.18. Philippines
      • 14.4.18.1. Overview
      • 14.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.18.3. Philippines Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.18.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.18.5. Philippines Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.18.6. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.18.7. Philippines Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.18.8. Philippines Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.18.9. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.4.19. Rest of APAC
      • 14.4.19.1. Overview
      • 14.4.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.4.19.3. Rest of APAC Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.4.19.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.4.19.5. Rest of APAC Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.4.19.6. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.4.19.7. Rest of APAC Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.4.19.8. Rest of APAC Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.4.19.9. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 14.5. Latin America (LATAM)
    • 14.5.1. Overview
    • 14.5.2. Sarcoidosis Drug Key Manufacturers in Latin America
    • 14.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.5.4. LATAM Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 14.5.5. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 14.5.6. LATAM Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.5.7. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.5.8. LATAM Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.5.9. LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 14.5.10. LATAM Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.5.11. Brazil
      • 14.5.11.1. Overview
      • 14.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.11.3. Brazil Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.5.11.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.5.11.5. Brazil Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.11.6. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.11.7. Brazil Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.11.8. Brazil Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.5.11.9. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.5.12. Mexico
      • 14.5.12.1. Overview
      • 14.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.12.3. Mexico Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.5.12.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.5.12.5. Mexico Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.12.6. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.12.7. Mexico Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.12.8. Mexico Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.5.12.9. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.5.13. Argentina
      • 14.5.13.1. Overview
      • 14.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.13.3. Argentina Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.5.13.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.5.13.5. Argentina Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.13.6. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.13.7. Argentina Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.13.8. Argentina Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.5.13.9. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.5.14. Colombia
      • 14.5.14.1. Overview
      • 14.5.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.14.3. Colombia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.5.14.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.5.14.5. Colombia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.14.6. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.14.7. Colombia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.14.8. Colombia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.5.14.9. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.5.15. Rest of LATAM
      • 14.5.15.1. Overview
      • 14.5.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.5.15.3. Rest of LATAM Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.5.15.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.5.15.5. Rest of LATAM Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.5.15.6. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.5.15.7. Rest of LATAM Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.5.15.8. Rest of LATAM Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.5.15.9. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
  • 14.6. Middle East and Africa
    • 14.6.1. Overview
    • 14.6.2. Sarcoidosis Drug Key Manufacturers in Middle East and Africa
    • 14.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 14.6.4. Middle East and Africa Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
    • 14.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 14.6.6. Middle East and Africa Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
    • 14.6.7. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 14.6.8. Middle East and Africa Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
    • 14.6.9. Middle East and Africa Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
    • 14.6.10. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.11. Saudi Arabia
      • 14.6.11.1. Overview
      • 14.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.11.3. Saudi Arabia Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.11.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.11.5. Saudi Arabia Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.11.6. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.11.7. Saudi Arabia Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.11.8. Saudi Arabia Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.11.9. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.12. United Arab Emirates
      • 14.6.12.1. Overview
      • 14.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.12.3. United Arab Emirates Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.12.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.12.5. United Arab Emirates Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.12.6. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.12.7. United Arab Emirates Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.12.8. United Arab Emirates Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.12.9. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.13. Israel
      • 14.6.13.1. Overview
      • 14.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.13.3. Israel Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.13.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.13.5. Israel Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.13.6. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.13.7. Israel Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.13.8. Israel Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.13.9. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.14. Turkey
      • 14.6.14.1. Overview
      • 14.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.14.3. Turkey Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.14.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.14.5. Turkey Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.14.6. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.14.7. Turkey Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.14.8. Turkey Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.14.9. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.15. Algeria
      • 14.6.15.1. Overview
      • 14.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.15.3. Algeria Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.15.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.15.5. Algeria Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.15.6. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.15.7. Algeria Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.15.8. Algeria Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.15.9. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.16. Egypt
      • 14.6.16.1. Overview
      • 14.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.16.3. Egypt Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.16.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.16.5. Egypt Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.16.6. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.16.7. Egypt Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.16.8. Egypt Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.16.9. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
    • 14.6.17. Rest of MEA
      • 14.6.17.1. Overview
      • 14.6.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 14.6.17.3. Rest of MEA Market Size and Forecast, By Mechanism of Action, 2019 - 2032 (US$ Million)
      • 14.6.17.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 14.6.17.5. Rest of MEA Market Size and Forecast, By Drug, 2019 - 2032 (US$ Million)
      • 14.6.17.6. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 14.6.17.7. Rest of MEA Market Size and Forecast, By End-Use, 2019 - 2032 (US$ Million)
      • 14.6.17.8. Rest of MEA Market Size and Forecast, By Age Group, 2019 - 2032 (US$ Million)
      • 14.6.17.9. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)

15. Key Vendor Analysis- Sarcoidosis Drug Industry

  • 15.1. Competitive Benchmarking
    • 15.1.1. Competitive Dashboard
    • 15.1.2. Competitive Positioning
  • 15.2. Company Profiles
    • 15.2.1. Janssen Pharmaceutical Companies of Johnson & Johnson
    • 15.2.2. Pfizer Inc
    • 15.2.3. Amgen Inc.
    • 15.2.4. Bristol Myers Squibb
    • 15.2.5. Novartis AG
    • 15.2.6. Kinevant Sciences GmbH
    • 15.2.7. Molecure S.A
    • 15.2.8. aTyr Pharma
    • 15.2.9. Merck & Co., Inc
    • 15.2.10. Xentria
    • 15.2.11. United Therapeutics Corporation
    • 15.2.12. Relief Therapeutics
    • 15.2.13. Mallinckrodt
    • 15.2.14. AbbVie Inc.
    • 15.2.15. Kyorin Pharmaceutical Co., Ltd.
    • 15.2.16. Boehringer Ingelheim International GmbH
    • 15.2.17. Sanofi
    • 15.2.18. GSK plc.
    • 15.2.19. Theravance Biopharma
    • 15.2.20. Others

16. 360 Degree Analyst View

17. Appendix

  • 17.1. Research Methodology
  • 17.2. References
  • 17.3. Abbreviations
  • 17.4. Disclaimer
  • 17.5. Contact Us